103 related articles for article (PubMed ID: 31811505)
1. Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older.
Kim MH; Kim GM; Kim JH; Kim JY; Park HS; Park S; Cho YU; Park BW; Kim SI; Sohn J
Breast Cancer Res Treat; 2020 Feb; 179(3):687-697. PubMed ID: 31811505
[TBL] [Abstract][Full Text] [Related]
2. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.
Curtit E; Nerich V; Mansi L; Chaigneau L; Cals L; Villanueva C; Bazan F; Montcuquet P; Meneveau N; Perrin S; Algros MP; Pivot X
Oncologist; 2013 Jun; 18(6):667-74. PubMed ID: 23723333
[TBL] [Abstract][Full Text] [Related]
3. ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer.
Pinhel I; Hills M; Drury S; Salter J; Sumo G; A'Hern R; Bliss JM; Sestak I; Cuzick J; Barrett-Lee P; Harris A; Dowsett M;
Breast Cancer Res; 2012 Mar; 14(2):R46. PubMed ID: 22417870
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological Features and Long-Term Prognostic Role of Human Epidermal Growth Factor Receptor-2 Low Expression in Chinese Patients with Early Breast Cancer: A Single-Institution Study.
Kong ZQ; Liu LQ; Huang Q; Wang YT; Li JJ; Zhang Z; Wang XX; Liu CL; Zhang YD; Shao JK; Zhu YM; Chen YM; Liu M; Zhao WH
Biomed Environ Sci; 2024 May; 37(5):457-470. PubMed ID: 38843919
[TBL] [Abstract][Full Text] [Related]
5. Association of Independent Prognostic Factors and Treatment Modality With Survival and Recurrence Outcomes in Breast Cancer.
Nguyen D; Yu J; Reinhold WC; Yang SX
JAMA Netw Open; 2020 Jul; 3(7):e207213. PubMed ID: 32644137
[TBL] [Abstract][Full Text] [Related]
6. Low ATM protein expression in malignant tumor as well as cancer-associated stroma are independent prognostic factors in a retrospective study of early-stage hormone-negative breast cancer.
Feng X; Li H; Dean M; Wilson HE; Kornaga E; Enwere EK; Tang P; Paterson A; Lees-Miller SP; Magliocco AM; Bebb G
Breast Cancer Res; 2015 May; 17(1):65. PubMed ID: 25935535
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of Ki67 in Chinese women diagnosed with ER
Hu Y; Gu R; Zhao J; Yang Y; Liu F; Jin L; Chen K; Jia H; Wang H; Liu Q; Su F; Jia W
BMC Cancer; 2017 Jan; 17(1):28. PubMed ID: 28061893
[TBL] [Abstract][Full Text] [Related]
8. HER2 exon 27 mutations predict worse survival of breast cancer patients, especially in HER2-negative patients.
Si P; Chen T; Fang B; Yao J; Liu G; Chen H; Zhai B; Li W
Cancer Med; 2017 Dec; 6(12):2832-2839. PubMed ID: 29072371
[TBL] [Abstract][Full Text] [Related]
9. Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study.
Purdie CA; Baker L; Ashfield A; Chatterjee S; Jordan LB; Quinlan P; Adamson DJ; Dewar JA; Thompson AM
Br J Cancer; 2010 Aug; 103(4):475-81. PubMed ID: 20664587
[TBL] [Abstract][Full Text] [Related]
10. Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample.
Griggs JJ; Hamilton AS; Schwartz KL; Zhao W; Abrahamse PH; Thomas DG; Jorns JM; Jewell R; Saber ME; Haque R; Katz SJ
Breast Cancer Res Treat; 2017 Jan; 161(2):375-384. PubMed ID: 27900490
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013.
King TA; Lyman JP; Gonen M; Voci A; De Brot M; Boafo C; Sing AP; Hwang ES; Alvarado MD; Liu MC; Boughey JC; McGuire KP; Van Poznak CH; Jacobs LK; Meszoely IM; Krontiras H; Babiera GV; Norton L; Morrow M; Hudis CA
J Clin Oncol; 2016 Jul; 34(20):2359-65. PubMed ID: 27001590
[TBL] [Abstract][Full Text] [Related]
12. Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
Roussot N; Constantin G; Desmoulins I; Bergeron A; Arnould L; Beltjens F; Mayeur D; Kaderbhai C; Hennequin A; Jankowski C; Padeano MM; Costaz H; Jacinto S; Michel E; Amet A; Coutant C; Costa B; Jouannaud C; Deblock M; Levy C; Ferrero JM; Kerbrat P; Brain E; Mouret-Reynier MA; Coudert B; Bertaut A; Ladoire S
Eur J Cancer; 2024 May; 202():114037. PubMed ID: 38554542
[TBL] [Abstract][Full Text] [Related]
13. Performance of a novel spectroscopy-based tool for adjuvant therapy decision-making in hormone receptor-positive breast cancer: a validation study.
Coombes RC; Angelou C; Al-Khalili Z; Hart W; Francescatti D; Wright N; Ellis I; Green A; Rakha E; Shousha S; Amrania H; Phillips CC; Palmieri C
Breast Cancer Res Treat; 2024 Jun; 205(2):349-358. PubMed ID: 38244167
[TBL] [Abstract][Full Text] [Related]
14. Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts.
Lundberg A; Lindström LS; Harrell JC; Falato C; Carlson JW; Wright PK; Foukakis T; Perou CM; Czene K; Bergh J; Tobin NP
Clin Cancer Res; 2017 Dec; 23(24):7512-7520. PubMed ID: 28972043
[No Abstract] [Full Text] [Related]
15. SIAH and EGFR, Two RAS Pathway Biomarkers, are Highly Prognostic in Locally Advanced and Metastatic Breast Cancer.
van Reesema LLS; Zheleva V; Winston JS; Jansen RJ; O'Connor CF; Isbell AJ; Bian M; Qin R; Bassett PT; Hinson VJ; Dorsch KA; Kirby BW; Van Sciver RE; Tang-Tan AM; Harden EA; Chang DZ; Allen CA; Perry RR; Hoefer RA; Tang AH
EBioMedicine; 2016 Sep; 11():183-198. PubMed ID: 27569656
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of receptor expression discordance between primary and recurrent breast cancers: a meta-analysis.
Shiino S; Ball G; Syed BM; Kurozumi S; Green AR; Tsuda H; Takayama S; Suto A; Rakha EA
Breast Cancer Res Treat; 2022 Jan; 191(1):1-14. PubMed ID: 34613502
[TBL] [Abstract][Full Text] [Related]
17. Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century.
Yadav S; Karam D; Bin Riaz I; Xie H; Durani U; Duma N; Giridhar KV; Hieken TJ; Boughey JC; Mutter RW; Hawse JR; Jimenez RE; Couch FJ; Leon-Ferre RA; Ruddy KJ
Cancer; 2020 Jan; 126(1):26-36. PubMed ID: 31588557
[TBL] [Abstract][Full Text] [Related]
18. Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer.
O Leary PC; Penny SA; Dolan RT; Kelly CM; Madden SF; Rexhepaj E; Brennan DJ; McCann AH; Pontén F; Uhlén M; Zagozdzon R; Duffy MJ; Kell MR; Jirström K; Gallagher WM
BMC Cancer; 2013 Apr; 13():175. PubMed ID: 23547718
[TBL] [Abstract][Full Text] [Related]
19. The emerging predictive and prognostic role of HER2 in HER2-negative early breast cancer: a retrospective study.
Corianò M; Tommasi C; Dinh ATL; Needham J; Aziz H; Joharatnam-Hogan N; Cunningham N; Waterhouse J; Sun M; Turkes F; Pellegrino B; McGrath S; Okines A; Parton M; Turner N; Johnston S; Musolino A; Ring A; Battisti NML
Breast Cancer Res Treat; 2024 May; ():. PubMed ID: 38743174
[TBL] [Abstract][Full Text] [Related]
20. Characteristics, healthcare utilization, and outcomes of patients with HER2-low breast cancer.
Check DK; Jackson BE; Reeder-Hayes KE; Dinan MA; Faherty E; Kwong J; Mehta S; Spees L; Wheeler SB; Wilson LE; Lam C
Breast Cancer Res Treat; 2024 Jan; 203(2):329-338. PubMed ID: 37875669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
